Breast Cancer Clinical Trial
Official title:
The Effect of Wearing a Compression Vest on Patient Reported Pain, Quality of Life and Degree of Breast Edema.
Verified date | January 2018 |
Source | UMC Utrecht |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A common complication of breast conserving therapy is breast edema, which may lead to chronic
pain, but also reduced quality of life (QoL) and poor cosmetic outcome. When pain is present
most patients are currently treated with physical therapy, but evidence of its effectiveness
is still low and a gold standard does not yet exist. A downside of physical therapy is that
patients have to undergo the therapy regularly and treatment might even has to continue for
years after symptoms and treatment started. Another treatment option is a compression vest
with the potential, apart from reducing symptoms, to improve self-efficacy in patients
because they decide when to wear it without the need to visit therapists. However
effectiveness of the compression vest has not yet been objectified in studies.
The aim of this pilot study is to study if there is an effect on pain, QoL and the amount of
breast edema of wearing a compression vest, in order to determine whether a large randomized
study is feasible.
Status | Completed |
Enrollment | 25 |
Est. completion date | January 2018 |
Est. primary completion date | January 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Females, aged 18 years and older. - Patient treated with surgery and/or radiotherapy for breast cancer, with symptomatic breast edema (e.g. pain). - Visual Analog Scale (VAS) pain score of 3 or more. Exclusion Criteria: - Inability to understand the Dutch language. - Indicated to undergo radiation treatment of the breast/chestwall within the next 6 months. - Cardiac complaints. - Pacemaker. - Port-a-cath. - Thrombosis of the arm. - Pulmonary embolism. - Pulmonary disease. - Pregnancy. - Non-breast cancer related lymph edema. - Clinical depression or anxiety disorder. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
UMC Utrecht | Thuasne |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effect of wearing a compression vest on patient reported outcome pain | Brief Pain Inventory (BPI) for pain questionnaire | At baseline | |
Primary | Effect of wearing a compression vest on patient reported outcome pain two weeks after wearing a compression vest | Brief Pain Inventory (BPI) for pain questionnaire | 2 weeks | |
Primary | Effect of wearing a compression vest on patient reported outcome pain one month after wearing a compression vest | Brief Pain Inventory (BPI) for pain questionnaire | 1 month | |
Primary | Effect of wearing a compression vest on patient reported outcome pain three months after wearing a compression vest | Brief Pain Inventory (BPI) for pain questionnaire | 3 months | |
Primary | Effect of wearing a compression vest on patient reported outcome pain six months after wearing a compression vest | Brief Pain Inventory (BPI) for pain questionnaire | 6 months | |
Secondary | Effect of wearing a compression vest on degree of breast edema (CTCAE score) | During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. | At baseline | |
Secondary | Effect of wearing a compression vest on degree of breast edema (CTCAE score) | During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. | At 1 month | |
Secondary | Effect of wearing a compression vest on degree of breast edema (CTCAE score) | During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. | At 3 months | |
Secondary | Effect of wearing a compression vest on degree of breast edema (CTCAE score) | During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. | At 6 months | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-C30 for quality of life and breast edema symptoms | At baseline | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-C30 for quality of life and breast edema symptoms | At 2 weeks after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-C30 for quality of life and breast edema symptoms | At 1 month after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-C30 for quality of life and breast edema symptoms | At 3 months after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-C30 for quality of life and breast edema symptoms | At 6 months after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-BR23 for quality of life and breast edema symptoms | At baseline | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-BR23 for quality of life and breast edema symptoms | At 2 weeks after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-BR23 for quality of life and breast edema symptoms | At 1 month after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-BR23 for quality of life and breast edema symptoms | At 3 months after wearing a compression vest | |
Secondary | Effect of wearing a compression vest on patient reported quality of life | EORTC QLQ-BR23 for quality of life and breast edema symptoms | At 6 months after wearing a compression vest |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |